Gilead poaches Bristol-Myers Squibb site head in continuing exec team remake
February 19, 2020 at 10:29 AM EST
Gilead, under new CEO Daniel O'Day, hires BMS's Redwood City site head, who has been focused on why immunotherapy drugs work in some cancers on some people and not others.
